Outsourcing

Articles

Under the agreement, ERS Genomics will license its gene-editing technology to Aelian Biotechnoloy to support its commercial functional genomic screening platform.

ERS Genomics, Aelian Biotechnology in CRISPR/Cas9 License Agreement

Alberto Santagostino is senior vice-president and head of cell and gene technologies at Lonza Pharma and Biotech. 

Contract partners must help innovators, especially smaller and virtual companies, consider manufacturability as early as possible in development. This requires focusing on technical and operational performance, as well as cost. 

Using the ‘Cubic Effect’ to Drive Cell and Gene Therapy Commercialization

Catalent builds on its investment in cell and gene therapy development and manufacturing with the acquisition of MaSTherCell Global.

Catalent to Acquire MaSTherCell Global for $315 Million

Shreekant Karmarkar, PhD, is president, DAT Pharma Consulting, Inc., skarmarkar@DATPharmaConsulting.com, 1-224-383-4493

How to adopt win-win strategies and understand quality agreements for complying with cGMP when building strategic relationships with pharmaceutical contract research organizations.

Building Strategic Relationships with CROs

CMOs and CDMOs expanded their services and facilities in 2019 and early 2020.

Pharma Contract Market Update

Rita Peters is the former editorial director of 

Pharmaceutical Technology, Pharmaceutical Technology Europe

The need for manufacturing speed inspires contract manufacturers to explore advanced processing technologies.

More Capacity and Technology Translate to More Options

Susan Haigney is lead editor of Pharmaceutical Technology and Pharmaceutical Technology Europe.

CDMOs and CMOs will continue to invest in biopharmaceutical services and facilities as the bio/pharmaceutical industry looks to biosimilars and personalized medicine.

Growth in Biologics Market Inspires Outsourcing

Drug development contract services company PPD announces initial public offering. 

PPD Launches IPO

The acquisition expands Charles River’s scientific capabilities in cell therapy development.

Charles River Laboratories to Acquire HemaCare in $380-Million Deal

Cambrex reports that the acquisition by the investment group will facilitate ongoing growth.

Contract Development Services